Taking stock of the drug industry, from the lab to the medicine chestFebruary 17, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | Government watchdog calls for stronger oversight of for-profit research review boards "The report's findings… are alarming," said U.S. Sen. Elizabeth Warren. "FDA and HHS should clean up the industry to keep patients safe." By Ed Silverman STAT+ | Pfizer scraps half of participants in Lyme disease drug trial due to quality issues Pfizer and partner Valneva's trial for a Lyme disease vaccine candidate hit a snag due to quality issues with a third-party trial operator. By Allison DeAngelis STAT+ | Christi Shaw, leader of Gilead's cancer cell therapy unit, to depart Christi Shaw, who took the CEO role in July 2019, was inspired to join Kite in part by the experience of watching her sister fight cancer. By Matthew Herper and Adam Feuerstein Adobe STAT+ | French court hands Novartis and Roche another win in battle over antitrust allegations involving eye drug This marks the second time this month that the pharmaceutical companies defeated a country's antitrust authorities. By Ed Silverman STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions, and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman STAT+ | Reata's 'toss up' drug approval decision is in the unpredictable hands of FDA's Billy Dunn Will Billy Dunn apply the doctrine of "regulatory flexibility" to a medicine from Reata with less-than-convincing clinical data? By Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments